Inhibition of GSK-3 reduces infarct volume and improves neurobehavioral functions
- 11 July 2008
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 371 (4), 894-899
- https://doi.org/10.1016/j.bbrc.2008.05.006
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Effect of 3-aminobenzamide, PARP inhibitor, on matrix metalloproteinase-9 level in plasma and brain of ischemic stroke modelToxicology, 2005
- Glycogen synthase kinase-3 in insulin and Wnt signalling: a double-edged sword?Biochemical Society Transactions, 2004
- The effect of PARP inhibitor on ischaemic cell death, its related inflammation and survival signalsEuropean Journal of Neuroscience, 2004
- Glycogen synthase kinase 3β inhibitor Chir025 reduces neuronal death resulting from oxygen-glucose deprivation, glutamate excitotoxicity, and cerebral ischemiaExperimental Neurology, 2004
- Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein inductionJournal of Neurochemistry, 2004
- GSK-3α regulates production of Alzheimer's disease amyloid-β peptidesNature, 2003
- Chronic Treatment With a Low Dose of Lithium Protects the Brain Against Ischemic Injury by Reducing Apoptotic DeathStroke, 2003
- Scaffold hopping and optimization towards libraries of glycogen synthase kinase-3 inhibitorsBioorganic & Medicinal Chemistry Letters, 2002
- AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim testInternational Journal of Neuropsychopharmacology, 1999
- Role of Glycogen Synthase Kinase-3 in the Phosphatidylinositol 3-Kinase/Akt Cell Survival PathwayJournal of Biological Chemistry, 1998